1-(2-(4-硝基苯氧基)乙基)吡咯啉 | 265654-77-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-(4-硝基苯氧基)乙基)吡咯啉
• 中文别名: 1-(2-(4-硝基苯氧基)乙基)吡咯烷
• 英文名称: 1-(2-(4-nitrophenoxy)ethyl)pyrrolidine
• 英文别名: 1-[2-(4-nitrophenoxy)ethyl]pyrrolidine
• CAS: 265654-77-1
• 化学式: C₁₂H₁₆N₂O₃
• mdl: MFCD01308390
• 分子量: 236.271
• InChiKey: RZIYRKYHMDDHCK-UHFFFAOYSA-N

物化性质

• 沸点：
  177-183 °C(Press: 2 Torr)
• 密度：
  1.195

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C，干燥密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(2-(4-Nitrophenoxy)ethyl)pyrrolidine
Synonyms: 4-(2-(pyrrolidinyl)ethoxy)-1-nitrobenzene

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(2-(4-Nitrophenoxy)ethyl)pyrrolidine
CAS number: 265654-77-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H16N2O3
Molecular weight: 236.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2-(4-硝基苯氧基)乙基)吡咯啉 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 生成 4-[2-(吡咯烷-1-基)乙氧基]苯胺
  参考文献：
  名称：

  鉴定一种新型 2,8-Diazaspiro[4.5]decan-1-one 衍生物作为治疗炎症性肠病的有效和选择性双 TYK2/JAK1 抑制剂

  摘要：

  在这项研究中，我们描述了一系列 2,8-diazaspiro[4.5]decan-1-one 衍生物作为选择性 TYK2/JAK1 抑制剂。通过引入基于报道的选择性 TYK2 抑制剂14l的螺环支架系统探索结构-活性关系导致发现了优越的衍生化合物48。化合物48对 TYK2/JAK1 激酶表现出优异的效力，IC 50值分别为 6 和 37 nM，对 JAK2 的选择性超过 23 倍。化合物48在急性溃疡性结肠炎模型中，还表现出比托法替尼更好的代谢稳定性和更有效的抗炎功效。此外，化合物48优异的抗炎作用是通过调节相关 TYK2/JAK1 调节基因的表达以及 Th1、Th2 和 Th17 细胞的形成来介导的。总之，这些发现表明化合物48是一种选择性的 TYK2/JAK 双重抑制剂，值得开发为临床候选药物。

  DOI：

  10.1021/acs.jmedchem.1c01137
• 作为产物：
  描述：

  2-(4-硝基苯氧基)乙醇 在 吡啶 、 氯化亚砜 、 potassium carbonate 、 potassium iodide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 1-(2-(4-硝基苯氧基)乙基)吡咯啉
  参考文献：
  名称：

  设计，合成，生物学评估和分子对接研究靶向ERα的新型3-芳基-4-苯胺基-2H-铬基-2-酮衍生物作为抗乳腺癌药物。

  摘要：

  雌激素受体（ER）在乳腺癌的发展和进程中起着重要作用，并且是抗癌药物发现的主要目标。为了开发新颖的选择性ERα调节剂（SERM），我们基于先前报道的先导化合物设计并合成了18种新颖的3-芳基-4-苯胺基-2H-色烯-2-酮衍生物。生物学结果表明，与阳性对照他莫昔芬相比，大多数化合物具有有效的ERα结合亲和力，并且对MCF-7和Ishikawa细胞系具有更好的抗增殖活性。哌啶基取代的化合物（例如16d和18d）分别具有很强的ERα结合亲和力和出色的抗增殖活性。化合物18d显示最有效的ERα结合亲和力，RBA值为2.83％，16d对MCF-7细胞表现出最佳的抗增殖活性，IC50值为4.52±2.47μM。还进行了进一步的分子对接研究，以研究新合成的化合物与ERα的结合模式。所有这些结果以及结构-活性关系（SAR）表明，这些具有碱性侧链的3-芳基-4-苯胺基-2H-铬-2-基衍生物可以作为进一步优化新型SERM的有前途的线索。

  DOI：

  10.1016/j.bmcl.2017.04.029
• 作为试剂：
  描述：

  N-(2-羟乙基)-吡咯烷 、 sodium;hydride 、 对氟硝基苯 、 在 氮气 、 碳酸氢钠 、 乙酸乙酯 、 Brine 、 magnesium sulfate 、 1-(2-(4-硝基苯氧基)乙基)吡咯啉 、 乙醇 、 钯 、 氢气 、 乙醇乙酸乙酯 、 silica gel 、 methanol-dichloromethane 作用下， 以 四氢呋喃 为溶剂， 25.0 ℃ 、41.37 MPa 条件下， 反应 51.58h， 以afforded 4-(2-pyrrolidin-1-ylethoxy)aniline as a brown oil的产率得到4-[2-(吡咯烷-1-基)乙氧基]苯胺
  参考文献：
  名称：

  Pyrimidinones as melanin concentrating hormone receptor 1

  摘要：

  提供了一个化合物(Ia)的公式，包括其药物可接受的盐或溶剂，以及其制剂、制备过程和哺乳动物的给药方法。

  公开号：

  US07285557B2

文献信息

• [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
  申请人：CEPHALON INC

  公开号：WO2010071885A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐形式，其中Q1、Q2、Q3和Q4如本文所定义。式（I）的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• [EN] ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'ISOQUINOLINONE UTILES DANS LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2016034642A1

  公开（公告）日：2016-03-10

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of cancer, as well as pharmaceutical compositions containing such a compound and processes to prepare such a compound.

  本发明涉及以下式（I）的化合物或其药学上可接受的盐和/或溶剂化合物，特别用作药物，特别用于治疗癌症，以及含有这种化合物的药物组合物和制备这种化合物的方法。
• [EN] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS<br/>[FR] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES ET 4-PYRAZOLYL-N-HÉTÉROARYLPYRIMIDIN-2-AMINES EN TANT QU'INHIBITEURS DE JANUS KINASE
  申请人：INCYTE CORP

  公开号：WO2009064835A1

  公开（公告）日：2009-05-22

  The present invention provides substituted bicyclic heteroaryl compounds, 5 including, for example, 4-pyrazoIyI-N-arylpyrirnidin-2-arnines and 4-pyrazolyl-N-heteroarylpyτimidin-2-amines that modulate the activity of kinases and are useful in the treatment of diseases related to activity of kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.formule :(1)

  本发明提供了取代的双环杂环芳基化合物，包括例如4-吡唑基-N-芳基吡啶-2-胺和4-吡唑基-N-杂环芳基嘧啶-2-胺，这些化合物调节激酶的活性，在治疗与激酶活性相关的疾病方面具有用处，例如免疫相关疾病、皮肤疾病、髓细胞增生性疾病、癌症和其他疾病。公式：(1)
• MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
  申请人：Zhao Guohua

  公开号：US20070185097A1

  公开（公告）日：2007-08-09

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1a , R 1b , R 1c , Q, A, R 3 , W, D and R 2 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  当前申请提供了根据公式I的化合物，包括所有立体异构体、溶剂化物、前药和药用可接受形式，其中R1a、R1b、R1c、Q、A、R3、W、D和R2按本文件定义。此外，当前申请还提供了含有至少一种根据公式I的化合物的药物组合物，以及可选的至少一种额外的治疗剂。最后，当前申请提供了通过给予根据公式I的化合物的治疗有效剂量，治疗患有MCHR-1调控疾病或失调的患者的方法，例如肥胖、糖尿病、抑郁症或焦虑症。
• Pyrrolopyrimidine Compounds and Their Uses
  申请人：Brain Christopher Thomas

  公开号：US20090318441A1

  公开（公告）日：2009-12-24

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.

  本申请描述了对治疗、预防及/或改善疾病有用的有机化合物，特别是描述了抑制蛋白激酶的吡咯并嘧啶化合物及其衍生物。这些有机化合物在治疗增殖性疾病中是有用的。